Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Verna Burdett

Psychiatry Woodbridge, VA Medical Doctor

NPI 1821168212 CMS profile 355669

13649 Office Place, Suite 102, Woodbridge, VA 22192

Open in the dashboard

General payments

$5,991

264 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Verna Burdett of Woodbridge, VA is reported in the CMS Open Payments database as having received $5,991 across 264 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $997 34
2024 General $952 39
2023 General $904 44
2022 General $731 40
2021 General $919 38
2020 General $523 17
2019 General $966 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Verna Burdett
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Verna Burdett were reported at $997. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Verna Burdett Psychiatry median Middle half National median
2019 $966 $184 $59–$605 $163
2020 $523 $119 $36–$372 $114
2021 $919 $143 $43–$576 $132
2022 $731 $153 $50–$590 $149
2023 $904 $170 $56–$651 $160
2024 $952 $179 $57–$673 $164
2025 $997 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $842 43 payments
  2. AbbVie, Inc. $547 24 payments
  3. Sunovion Pharmaceuticals Inc. $529 17 payments
  4. Lundbeck LLC $502 26 payments
  5. Tris Pharma Inc $414 19 payments
  6. Janssen Pharmaceuticals, Inc $409 18 payments
  7. Vanda Pharmaceuticals Inc. $396 12 payments
  8. ITI, Inc. $391 23 payments
  9. Supernus Pharmaceuticals, Inc. $345 12 payments
  10. Allergan Inc. $321 14 payments
  11. Other $1,296 56 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,979 263 payments
  2. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. REXULTI Psychiatry $842 43 payments
  2. LATUDA $529 17 payments
  3. VRAYLAR Neuroscience $509 20 payments
  4. REXULTI Psychiatry $444 23 payments
  5. SPRAVATO $409 18 payments
  6. FANAPT $396 12 payments
  7. VRAYLAR Neuroscience $360 18 payments
  8. QELBREE $304 10 payments
  9. Dyanavel XR $295 11 payments
  10. CAPLYTA $248 15 payments
  11. Other $2,427 107 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

603

Median for Psychiatry & Neurology: 100

Drug cost

$27,971

Median for Psychiatry & Neurology: $2,986

Branded share of claims

23.2%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 11 $17,494
Paliperidone Er Paliperidone Brand 22 $2,145
Aripiprazole Generic 53 $1,629
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 16 $1,605
Buspirone Hcl Generic 17 $859
Escitalopram Oxalate Generic 74 $596
Ramelteon Generic 13 $583
Fluoxetine Hcl Generic 41 $541
Clonazepam Generic 49 $437
Quetiapine Fumarate Generic 34 $397

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $164
  • Lundbeck LLC $105
$268 11 —
FANAPT
  • Vanda Pharmaceuticals Inc. $232
$232 — —
Dyanavel XR
  • Tris Pharma Inc $110
$111 — —
VRAYLAR
  • AbbVie, Inc. $69
$69 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $51
$51 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

264 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record